Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $495.00 at Piper Sandler

Intuitive Surgical (NASDAQ:ISRG) had its price objective lifted by stock analysts at Piper Sandler from $490.00 to $495.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s target price would suggest a potential upside of 8.79% from the company’s previous close.

ISRG has been the topic of several other research reports. Truist Financial lifted their price target on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. BTIG Research boosted their target price on Intuitive Surgical from $451.00 to $459.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Jefferies Financial Group boosted their target price on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Stifel Nicolaus boosted their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Finally, Citigroup boosted their target price on Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $438.74.

Intuitive Surgical Trading Up 9.3 %

ISRG stock opened at $455.01 on Friday. Intuitive Surgical has a 12-month low of $254.85 and a 12-month high of $456.81. The stock has a market cap of $161.39 billion, a price-to-earnings ratio of 82.13, a PEG ratio of 5.37 and a beta of 1.39. The business’s 50-day moving average is $422.05 and its 200 day moving average is $394.21.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.40% and a net margin of 27.65%. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.18 EPS. As a group, equities analysts forecast that Intuitive Surgical will post 4.8 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 1,498 shares of the business’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the transaction, the executive vice president now owns 5,507 shares in the company, valued at $2,037,149.44. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $421.06, for a total transaction of $589,484.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Desantis sold 1,498 shares of the business’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $369.92, for a total transaction of $554,140.16. Following the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,956 shares of company stock worth $6,927,011. Corporate insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

Several large investors have recently bought and sold shares of the stock. Indiana Trust & Investment Management CO boosted its stake in Intuitive Surgical by 5.3% in the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 25 shares in the last quarter. Hoxton Planning & Management LLC raised its holdings in shares of Intuitive Surgical by 4.9% in the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 25 shares during the last quarter. First Affirmative Financial Network raised its holdings in shares of Intuitive Surgical by 2.7% in the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after buying an additional 26 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in shares of Intuitive Surgical by 0.3% in the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock valued at $3,002,000 after buying an additional 27 shares during the last quarter. Finally, Advance Capital Management Inc. raised its holdings in shares of Intuitive Surgical by 3.8% in the first quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock valued at $295,000 after buying an additional 27 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.